A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

Not yet recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

IgA Nephropathy (IgAN)Early Initial Therapy

Interventions

OTHER

Gd-IgA1 test

collect and test Gd-IgA1 test in enrolled subjects

All Listed Sponsors

lead

Sichuan Provincial People's Hospital

OTHER